{"event":"anxiety-tracker","title":"Anxiety research and policy tracker: drugs, trials and guidance","state":"developing","updated":"2026-10-11T00:00:00.000Z","entries":[{"id":"nglpl5","at":"2026-09-17T00:00:00.000Z","title":"New USPSTF members named after a year without meetings","status":"confirmed","body":"The Task Force, which issued the 2023 anxiety screening recommendation, had not met for over a year; HHS Secretary Robert F. Kennedy Jr. named eight new members.","cites":[{"id":"health-cancer-uspstf-not-met","n":21,"url":"https://www.statnews.com/2026/09/17/kennedy-names-eight-new-members-uspstf-task-force/","publisher":"STAT","short":"STAT"},{"id":"health-cancer-uspstf-new-members","n":22,"url":"https://www.statnews.com/2026/09/17/kennedy-names-eight-new-members-uspstf-task-force/","publisher":"STAT","short":"STAT"}]},{"id":"1kwdt3c","at":"2026-09-15T00:00:00.000Z","title":"WHO updates anxiety fact sheet to 470 million people","status":"confirmed","body":"WHO says only about 1 in 4 people who need treatment receive any.","cites":[{"id":"mh-anxiety-who-470m","n":6,"url":"https://www.who.int/news-room/fact-sheets/detail/anxiety-disorders","publisher":"World Health Organization","short":"World Health Organization"},{"id":"mh-anxiety-who-treatment-gap","n":26,"url":"https://www.who.int/news-room/fact-sheets/detail/anxiety-disorders","publisher":"World Health Organization","short":"World Health Organization"}]},{"id":"1wvcz1c","at":"2026-09-14T00:00:00.000Z","title":"DT120 meets primary endpoint in second phase 3 GAD trial (Panorama)","status":"confirmed","body":"A 5.1-point placebo-adjusted HAM-A reduction at week 12; Definium scheduled a pre-NDA meeting for late 2026.","cites":[{"id":"mh-anxiety-panorama-results","n":2,"url":"https://www.sec.gov/Archives/edgar/data/0001813814/000110465926107275/tm2625365d1_ex99-1.htm","publisher":"Definium Therapeutics (SEC filing)","short":"Definium Therapeutics"},{"id":"mh-anxiety-dt120-nda-plan","n":3,"url":"https://www.sec.gov/Archives/edgar/data/0001813814/000110465926107275/tm2625365d1_ex99-1.htm","publisher":"Definium Therapeutics (SEC filing)","short":"Definium Therapeutics"}]},{"id":"1vqzxr9","at":"2026-08-12T00:00:00.000Z","title":"DT120 meets primary endpoint in first phase 3 GAD trial (Voyage)","status":"reported","body":"Company-reported topline results; a single 100 µg dose cut HAM-A scores 5.4 points more than placebo at week 12.","cites":[{"id":"mh-anxiety-voyage-results","n":1,"url":"https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder","publisher":"Definium Therapeutics (press release)","short":"Definium Therapeutics"},{"id":"mh-anxiety-voyage-safety","n":14,"url":"https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder","publisher":"Definium Therapeutics (press release)","short":"Definium Therapeutics"}]},{"id":"1qxox52","at":"2026-06-30T00:00:00.000Z","title":"Fasedienol also misses in PALISADE-4","status":"confirmed","body":"A post-hoc analysis suggested a nominal benefit in very severe social anxiety; Vistagen planned to discuss a single further trial with the FDA.","cites":[{"id":"mh-anxiety-palisade4","n":5,"url":"https://www.financialcontent.com/article/bizwire-2026-6-30-vistagen-announces-topline-and-post-hoc-data-from-palisade-4-phase-3-public-speaking-challenge-trial-of-fasedienol-for-the-acute-treatment-of-social-anxiety-disorder","publisher":"Vistagen (press release via Business Wire)","short":"Vistagen"}]},{"id":"13q6h4s","at":"2025-12-17T00:00:00.000Z","title":"Fasedienol misses primary endpoint in PALISADE-3","status":"confirmed","body":"Vistagen's nasal spray for acute social anxiety did not beat placebo during a simulated public-speaking challenge.","cites":[{"id":"mh-anxiety-palisade3","n":4,"url":"https://finance.yahoo.com/news/vistagen-announces-topline-results-palisade-133000285.html","publisher":"Vistagen (press release via Business Wire)","short":"Vistagen"}]},{"id":"1jm8l80","at":"2025-10-21T00:00:00.000Z","title":"JAMA publishes phase 2b trial of single-dose MM120 in GAD","status":"confirmed","body":"The 100 µg and 200 µg doses reduced anxiety scores at week 4 versus placebo; visual perceptual changes were common.","cites":[{"id":"mh-anxiety-mm120-phase2b","n":13,"url":"https://pubmed.ncbi.nlm.nih.gov/40906494/","publisher":"JAMA (via PubMed)","short":"JAMA"},{"id":"mh-anxiety-mm120-phase2b-effects","n":16,"url":"https://pubmed.ncbi.nlm.nih.gov/40906494/","publisher":"JAMA (via PubMed)","short":"JAMA"}]},{"id":"sx28i9","at":"2025-01-02T00:00:00.000Z","title":"Large trial finds digital meditation cuts employee stress","status":"confirmed","body":"1,458 employees at a US academic medical center; effects held at 4 months.","cites":[{"id":"mh-anxiety-radin-employee-rct","n":25,"url":"https://pubmed.ncbi.nlm.nih.gov/39808431/","publisher":"JAMA Network Open (via PubMed)","short":"JAMA Network Open"}]},{"id":"19tlnao","at":"2024-09-05T00:00:00.000Z","title":"FDA clears DaylightRx, the first digital treatment for GAD","status":"confirmed","body":"A prescription CBT app from Big Health for adults aged 22 and older, used alongside usual care.","cites":[{"id":"mh-anxiety-daylightrx-clearance","n":10,"url":"https://www.psychiatrictimes.com/view/first-digital-treatment-for-generalized-anxiety-disorder-cleared-by-the-fda","publisher":"Psychiatric Times","short":"Psychiatric Times"}]},{"id":"v8wjx2","at":"2023-06-20T00:00:00.000Z","title":"USPSTF recommends anxiety screening for adults 64 and younger","status":"confirmed","body":"A new grade B recommendation that includes pregnant and postpartum people; evidence for adults 65 and older was rated insufficient.","cites":[{"id":"mh-anxiety-uspstf-grade-b","n":19,"url":"https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/anxiety-adults-screening","publisher":"US Preventive Services Task Force","short":"US Preventive Services…"},{"id":"mh-anxiety-uspstf-older-i","n":20,"url":"https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/anxiety-adults-screening","publisher":"US Preventive Services Task Force","short":"US Preventive Services…"}]},{"id":"1hgnbhm","at":"2020-09-23T00:00:00.000Z","title":"FDA requires updated boxed warnings on all benzodiazepines","status":"confirmed","body":"The warnings cover abuse, addiction, physical dependence and withdrawal reactions.","cites":[{"id":"mh-anxiety-fda-benzo-2020","n":24,"url":"https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class","publisher":"US Food and Drug Administration","short":"US Food and Drug…"},{"id":"mh-anxiety-fda-benzo-dependence","n":23,"url":"https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class","publisher":"US Food and Drug Administration","short":"US Food and Drug…"}]}]}